文献速递其他结缔组织病

表观遗传调控作为系统性硬化症的治疗策略

Epigenetic modulation as a therapy in systemic sclerosis.
PubMed 文献 · Rheumatology (Oxford) · 2019-01-01

本文综述系统性硬化症中参与肌成纤维细胞生成与调控的表观遗传修饰,以及细胞因子和激素对这些修饰的调节作用,并探讨以表观遗传调控因子为靶点的治疗可能,包括微小RNA(miRNA)替代等表观遗传药物的开发。

要点

  • 系统性硬化症中炎症成分驱动纤维化,主要效应细胞为活化的肌成纤维细胞。
  • 表观遗传修饰正负调控肌成纤维细胞生成,并可被多种细胞因子和激素激活与调节。
  • 表观遗传调控为系统性硬化症提供新的治疗靶点,miRNA替代等表观遗传药物正在开发。

核心结论

  • 表观遗传修饰对肌成纤维细胞生成和系统性硬化症的贡献正逐渐被揭示,为该病开辟了新的治疗靶点。

研究设计与样本

  • 本文为综述,检视系统性硬化症中的表观遗传调控因子及针对这些因子的可能靶向策略。

主要发现

  • 系统性硬化症为自身免疫性特发性疾病,炎症成分驱动纤维化,主要累及皮肤和肺。
  • 活化的肌成纤维细胞分泌大量细胞外基质形成沉积,导致僵硬和纤维化。
  • 表观遗传修饰正负调控肌成纤维细胞生成,并可被多种细胞因子和激素激活和调节。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SSc is an autoimmune idiopathic disease in which there is an inflammatory component driving fibrosis. The chief cell involved is the myofibroblast, which when activated secretes copious amounts of extracellular matrix that forms deposits, leading to stiffness and fibrosis. The fibrosis is most prevalent in the skin and lungs. In recent years epigenetic modifications have been uncovered that positively and negatively regulate the genesis of the myofibroblasts and that can be activated and regulated by a variety of cytokines and hormones. The epigenetic contribution to these cells and to SSc is only now really coming to light, and this opens up a new therapeutic target for the disease for which many epigenetic drugs, such as miRNA replacements, are beginning to be developed. This review will examine the epigenetic regulators in the disease and possible targeting of these.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. O'Reilly S. Epigenetic modulation as a therapy in systemic sclerosis. Rheumatology (Oxford). 2019. PMID: 29579252. doi:10.1093/rheumatology/key071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。